Abstract
Venous thromboembolism is a common condition and low molecular weight heparins (LMWHs) are widely used for its treatment. Chronic kidney disease (CKD) is also a frequent disease especially in subjects with comorbidities admitted to internal medicine wards. LMWHs are eliminated by the kidney and their half-life is increased in renal impairment. Based on a series of available studies we analyzed the relationship between treatment with LMWHs and different degrees of renal impairment including end-stage renal disease (ESRD). In order to reduce haemorrhagic risk, the LMWH dose should be reduced in CKD, even if reducing LMWH dose could impair drug effectiveness. Further studies relating glomerular filtration rate to LMWH effectiveness and side effects are required.
Keywords: Low molecular heparin, chronic kidney disease, dialysis, glomerular filtration rate, thromboembolism, acute coronary syndrome, atrial fibrillation, ischaemic stroke, cardiomyopathy, plasminogen activator inhibitor type 1
Current Vascular Pharmacology
Title: Low Molecular Weight Heparins and Glomerular Filtration Rate: A Report to be Considered
Volume: 9 Issue: 6
Author(s): Fabio Fabbian, Alfredo De Giorgi, Marco Pala, Ruana Tiseo, Francesco Portaluppi, Davide Imberti and Roberto Manfredini
Affiliation:
Keywords: Low molecular heparin, chronic kidney disease, dialysis, glomerular filtration rate, thromboembolism, acute coronary syndrome, atrial fibrillation, ischaemic stroke, cardiomyopathy, plasminogen activator inhibitor type 1
Abstract: Venous thromboembolism is a common condition and low molecular weight heparins (LMWHs) are widely used for its treatment. Chronic kidney disease (CKD) is also a frequent disease especially in subjects with comorbidities admitted to internal medicine wards. LMWHs are eliminated by the kidney and their half-life is increased in renal impairment. Based on a series of available studies we analyzed the relationship between treatment with LMWHs and different degrees of renal impairment including end-stage renal disease (ESRD). In order to reduce haemorrhagic risk, the LMWH dose should be reduced in CKD, even if reducing LMWH dose could impair drug effectiveness. Further studies relating glomerular filtration rate to LMWH effectiveness and side effects are required.
Export Options
About this article
Cite this article as:
Fabbian Fabio, De Giorgi Alfredo, Pala Marco, Tiseo Ruana, Portaluppi Francesco, Imberti Davide and Manfredini Roberto, Low Molecular Weight Heparins and Glomerular Filtration Rate: A Report to be Considered, Current Vascular Pharmacology 2011; 9 (6) . https://dx.doi.org/10.2174/157016111797484170
DOI https://dx.doi.org/10.2174/157016111797484170 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stress Hormone-Mediated DNA Damage Response -- Implications for Cellular Senescence and Tumour Progression
Current Drug Targets Toxicology of Trastuzumab: An Insight into Mechanisms of Cardiotoxicity
Current Cancer Drug Targets Cirrhotic Cardiomyopathy: The Interplay Between Liver and Cardiac Muscle. How Does the Cardiovascular System React When the Liver is Diseased?
Current Cardiology Reviews Positron Emitting Tracers in Pre-Clinical Drug Development
Current Radiopharmaceuticals The Application of NMR Spectroscopy for the Study of Heart Failure
Current Pharmaceutical Design The Mechanism of Carvedilol in Experimental Viral Myocarditis
Current Pharmaceutical Design Mitochondrial Biogenesis: Regulation By Endogenous Gases During Inflammation and Organ Stress
Current Pharmaceutical Design Development of Aldose Reductase Inhibitors for the Treatment of Inflammatory Disorders and Cancer: Current Drug Design Strategies and Future Directions
Current Medicinal Chemistry Patent Selections:
Recent Patents on Drug Delivery & Formulation Regulatory Light Chains of Striated Muscle Myosin. Structure, Function and Malfunction
Current Drug Targets - Cardiovascular & Hematological Disorders Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery New Insights in Research About Acute Ischemic Myocardial Injury and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Obesity, Diabetes and Atrial Fibrillation; Epidemiology, Mechanisms and Interventions
Current Cardiology Reviews Lipid Lowering Agents and the Endothelium: An Update after 4 Years
Current Vascular Pharmacology Clinical Approach to Diabetic Cardiomyopathy: A Review of Human Studies
Current Medicinal Chemistry Atherogenesis in Renal Patients: A Model of Vascular Disease?
Current Vascular Pharmacology Study of Prolactin Permeation Through the Pericardium and Its Bioavailability
Protein & Peptide Letters Therapeutic Potential of Endothelial Progenitor Cells for Cardiovascular Diseases
Current Vascular Pharmacology Drug-induced Cardiac Mitochondrial Toxicity and Protection: From Doxorubicin to Carvedilol
Current Pharmaceutical Design Does More MnSOD Mean More Hydrogen Peroxide?
Anti-Cancer Agents in Medicinal Chemistry